Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.9945
-0.0055 (-0.55%)
Oct 8, 2026, 1:29 PM EDT - Market open
Ocugen Revenue
Ocugen had revenue of $1.49M in the quarter ending June 30, 2026, with 8.38% growth. This brings the company's revenue in the last twelve months to $4.58M, down -3.66% year-over-year. In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth. That makes Ocugen the 40,218th largest company in the world by revenue and 5,361st in the United States.
Revenue (ttm)
$4.58M
Revenue Growth
-3.66%
P/S Ratio
72.63
Revenue / Employee
$39,491
Employees
116
Market Cap
337.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.41M | 358.00K | 8.83% |
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| C4 Therapeutics | 35.04M |
| Scribe Therapeutics | 33.30M |
| Orchestra BioMed Holdings | 31.98M |
| Arcturus Therapeutics Holdings | 29.37M |
| Artiva Biotherapeutics | 251.00K |
OCGN News
- 22 hours ago - Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update - Newsfile Corp
- 2 days ago - Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate - GlobeNewsWire
- 3 days ago - Ocugen Transcript: EGM 2026 - Transcripts
- 8 days ago - Ocugen to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 9 days ago - Ocugen to Participate in Upcoming October Investor and Industry Conferences - GlobeNewsWire
- 13 days ago - Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa - GlobeNewsWire
- 17 days ago - Ocugen Transcript: EGM 2026 - Transcripts
- 22 days ago - Ocugen Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts